Vered Caplan - Orgenesis Insider

ORGS -- USA Stock  

USD 8.08  0.14  1.70%

Chairman of the Board, Interim President and CEO
Ms. Vered Caplan serves as Chairman of the Board, Chief Executive Officer, President of the Company and Chief Executive Officer of Orgenesis Maryland Inc, a subsidiary of the Company. Vered Caplan was appointed President and CEO on August 14, 2014, prior to which she was Interim President and CEO since December 23, 2013. Since 2008, Ms. Caplan was Chief Executive Officer of Kamedis, a company focused on utilizing plant extracts for dermatology purposes. From 2004 to 2007, Ms. Caplan was Chief Executive Officer of GammaCan, a company focused on the use of immunoglobulins for treatment of cancer. During the previous five years, Ms. Caplan was a director of the following companies Opticul Ltd., a company involved with optic based bacteria classification Inmotion Ltd., a company involved with selfpropelled disposable colonoscopies Nehora Photonics Ltd., a company involved with noninvasive blood monitoring Ocure Ltd., a company involved with wound management Eve Medical Ltd., a company involved with hormone therapy for Menopause and PMS and Biotech Investment Corporationration, a company involved with prostate cancer diagnostics
Age: 45  Chairman Since 2016      
Caplan has a M.Sc. in biomedical engineering from TelAviv University specializing in signal processing; management for engineers from TelAviv University specializing in business development; and a B.Sc. in mechanical engineering from the Technion specialized in software and cad systems.

Management Efficiency

The company has return on total asset (ROA) of (16.08) % which means that it has lost $16.08 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (80.6) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 4.53 M in liabilities with Debt to Equity (D/E) ratio of 19.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Orgenesis has Current Ratio of 0.52 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Entity Summary

Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in USA and traded on OTC Market. It employs 103 people.Orgenesis (ORGS) is traded on BATS Exchange in USA. It is located in MARYLAND U.S.A and employs 103 people. Orgenesis is listed under Pharmaceutical Products category by Fama And French industry classification.

Orgenesis Leadership Team

David Sidransky, Director
Yaron Adler, Director
Marie Bouillez, Director
Neil Reithinger, CFO
Scott Carmer, CEO
Etti Hanochi, Director, MBA
Hugues Bultot, Director
Guy Yachin, Director, MBA
Chris Buyse, Director
Vered Caplan, Chairman
Sarah Ferber, Executive

Stock Performance Indicators

Current Sentiment - ORGS

Orgenesis Investor Sentiment
Most of Macroaxis users are now bullish on Orgenesis. What is your perspective on investing in Orgenesis? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally take a look at Your Equity Center. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.